anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Polycystic ovary yndrome (PCOS) is a common metabolic disorder in women, which is usually associated with insulin resistance (IR) and chronic inflammation. Loureirin B (LrB) can effectively improve insulin resistance and alleviate chronic inflammation, and in order to investigate the therapeutic effect of LrB on polycystic ovary syndrome with insulin resistance (PCOS-IR), we conducted animal experiments. A PCOS-IR rat model was established by feeding a high-fat diet combined with letrozole (1 mg/kg·d for 21 days). The rats were treated with the GPR120 agonists TUG-891 and LrB for 4 weeks. Biochemical parameters (fasting blood glucose, total cholesterol, triglycerides, high- and low-density lipoprotein), hormone levels (serum insulin, E2, T, LH, and FSH), and inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-18) were analyzed. Histopathological analyses of ovaries were performed using hematoxylin/eosin (H&E) staining. Real-time PCR and western blotting were used to assess GPR120, NLRP3, and caspase-1 expression in ovaries, and immunohistochemistry was used to evaluate LKB1 and AMPK protein expression. LrB reduced body weight, Lee's index, ovarian index, ovarian area, and volume in PCOS-IR rats. It lowered fasting blood glucose, serum insulin, and HOMA-IR. LrB decreased total serum cholesterol, triglyceride, and LDL levels and increased HDL levels. It reduced serum T, LH, and LH/FSH and raised serum E2 and FSH levels. LrB downregulated the mRNA and protein expression levels of NLRP3 and Caspase-1, increased the protein and mRNA expression levels of GPR120 in rat ovaries, and increased LKB1 and AMPK protein expression in ovaries, ameliorating ovarian histopathological changes in PCOS-IR rats. Taken together, LrB upregulated GPR120, LKB1, and AMPK protein expression, downregulated NLRP3 and Caspase-1 protein expression, reduced insulin resistance and chronic inflammation, and ameliorated histopathological changes in ovarian tissues in PCOS rats, suggesting its potential as a treatment for PCOS.
A Ca salt with high solubility and a high Ca content suitable for therapeutic administration is prepd. by dissolving 1 part of a mixt. of Ca gluconate and Ca lactate in a ratio of 1:0.4, 1:0.6, 1:0.9 or 1:1.05 in 2-4 parts H2O, concentrating the soln. to give a ratio of salt to H2O of 1:1 or 2:1 by boiling up for 20-120 mins. and pptg. the salt with an org. solvent or isolating it by spray drying.
Maternal obesity leads to increased insulin resistance and inflammation which have been shown to induce fetal adaptations and greater risk of obesity in the offspring. Probiotic supplementation during pregnancy has been shown to improve insulin sensitivity in normal weight women. However, little is known on the effects of probiotic supplementation throughout pregnancy on maternal insulin sensitivity and inflammation as well as offspring gene expression and body composition. Long term nutritional supplementation, however, is associated with increased participant burden as well as lower compliance and retention rates. Thus, this study will assess the feasibility of a long term probiotic supplementation study in obese pregnant women. Acceptance and compliance with daily capsules throughout pregnancy and study procedures will be assessed.
Improved very high viscosity (putty) two component polymerizable polyorganosiloxane composition for use in making dental impressions, having improved tear strength, handling and wettability. Improved tear strength results from inclusion of a quadri-functional polysiloxane having a vinyl content of 0.16 to 0.24 m-mole/g. Working time is maintained by including sufficient amounts of a retarder composition that delays onset of the vinyl polymerization. Handling is improved by the addition of a very high viscosity linear vinyl terminated polydimethylsiloxane which reduces tackiness and improves the shelf stability. Wettability is improved by including a surfactant resulting in a surface contact angle with water at three minutes of less than 50°. The surfactant chosen has an HLB of 8-11, such that the wetting contact angle is achieved within less than two minutes and remains wetting throughout the working time of the impression taking, substantially improving the impression making process.
OBJECTIVE: Ultrasound (US) is a common imaging modality used to evaluate spinal anomalies in newborns. However, many indications for the use of spinal US are associated with low diagnostic yield. The purpose of this study is to evaluate the indications and the diagnostic utility of spinal USs performed in newborns at our institution. We also review patient presentations for caudal regression syndrome (CRS) that was identified from the USs performed.
STUDY DESIGN: This study is a retrospective review of spinal USs performed between January 1, 2006, and December 31, 2021, in newborns at a single institution. Indications for each US and any associated abnormalities were noted. Infants with abnormal USs showing CRS are described with their long-term medical outcomes.
RESULTS: A total of 592 USs were performed during the specified time period of which 72 (12%) were abnormal. The presence of a sacral dimple was the most common indication for performing a spinal US, although only 14 (4%) were identified as abnormal. Of these 14, 6 (43%) were further evaluated by spinal magnetic resonance imaging (MRI) at the recommendations of a pediatric radiologist and of these, only 2 (14%) had abnormal MRI findings. The two newborns with abnormal MRI findings had mothers with diabetes mellitus in their pregnancies. Of note, one additional newborn had abnormalities on spinal US that was never confirmed on MRI due to being lost to follow-up. Among the other indications, anorectal anomalies (odds ratio [OR], 7.55; 95% confidence interval [CI], 3.01-18.91), spinal mass (OR, 17.99; 95% CI, 7.86-41.2), and meningocele were most associated with abnormal findings.
CONCLUSION: Overall, spinal US has a low diagnostic yield. Sacral dimple was the most common indication for performing a spinal US but had a low yield with few long-term sequelae. Anorectal anomalies had a strong association with abnormal US findings.
KEY POINTS: · Sacral dimple is a common indication for spinal ultrasound.. · Spinal ultrasound has low diagnostic yield when performed for sacral dimple.. · Caudal regression syndrome is associated with maternal diabetes and numerous long-term comorbidities..
Despite significant declines in cigarette smoking rates among adults in the United States in the last few decades, smoking rates remain high among poor and underserved populations. One underserved group is the 4 million homeless persons in the US among whom cigarette smoking rate is an alarming 70% or more; these rates are 3 times higher than national average. Two of the three leading causes of death among homeless persons, heart disease and cancer are tobacco related.2, 3 Despite very high smoking prevalence and disease burden in this population smoking cessation research have not been extended to the homeless. Recent studies including data from our research team show a considerable degree of readiness to quit smoking by homeless smokers and that nicotine replacement therapy (NRT) plus counseling show promise. However, homeless persons face many challenges that may constitute barriers for them to adhere to smoking cessation treatments even if such treatments have been proven effective in the general population. In order to reduce smoking-related health disparities within this underserved population, it is critical that cessation interventions including strategies to improve treatment adherence be developed to include homeless smokers. The primary aim of this study is to assess the effects of adherence-focused motivational interviewing (MI) to help homeless persons quit smoking.

Recruitment and retention will be enhanced by use of bus passes for transportation, debit cards, attractive intervention materials, collaboration with homeless shelters, and advice from a community advisory board. If successful, this study will provide a model for how to overcome barriers to cancer prevention services among homeless persons. It will also provide the impetus for policy changes directed at increasing homeless persons' access to smoking cessation pharmacotherapy and treatment.
PURPOSE: An ophthalmic composition which is useful for treating allergic conjunctivitis without irritation to the eyes is provided. CONSTITUTION: An ophthalmic composition contains desloratadine, glucose, concentrated glycerin or mixture thereof. The composition additionally contains pharmaceutically acceptable additive of viscosity modifier, solubilizing agent, stabilizer, buffer agent, preserver, PH adjusting agent or isotonising agent. Deslortadine is contained 0.001-5.0%(w/v) based on total composition. The composition contains hydroxypropyl methylcellulose as a viscosity modifier. The composition is used in the form of eye drop, ophthalmic lotion, ointment or cream.
PURPOSE: Novel agents such as PI3K and mTOR inhibitors (PI3K/mTORi) have expanded treatment options in metastatic breast cancer (MBC). Nevertheless, mortality rates remain disproportionately high for Black patients and patients with lower socioeconomic status. Furthermore, clinical trials for these novel agents lacked diversity, so their toxicity profile in minority populations is uncertain.
METHODS: We conducted a retrospective analysis of EHR-derived data from the Flatiron Health Database for patients with HR+, HER2- MBC. Multivariable logistic regression was used to evaluate factors associated with PI3K/mTORi use and toxicity outcomes.
RESULTS: A total of 9169 patients with MBC were included in our analysis, of which 1780 (19.4%) received a PI3K/mTORi. We estimated the conditional total effect of insurance through Medicaid, and found lower odds of use of PI3K/mTORi among patients on Medicaid compared to those with commercial insurance (OR 0.73, 95% CI 0.54-0.99, p = 0.049). Odds of PI3K/mTORi use were higher for patients treated at an academic center (OR 1.28, CI 1.06-1.55, p = 0.01). Modeled as a controlled direct effect, Black/African American (Black/AA) race had no impact on odds of PI3K/mTOR use. Black/AA patients had twice the odds of developing hyperglycemia on PI3K/mTORi compared to White patients (OR 2.02, CI 1.24-3.39, p < 0.01).
CONCLUSION: This analysis of real-world data suggests that the use of PI3K/mTORi is influenced by socioeconomic factors. We also found racial disparities in toxicity outcomes, with Black/AA patients having twice the risk of hyperglycemia. Our findings call for greater efforts to ensure access to novel treatments and improve their tolerability in diverse populations.
Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc). Zevalin® will be delivered as per indications and should thus be provided at expenses following regular supplies procedures.
The present invention is directed to molecules (e.g., an antibody, a diabody, an scFv, an antibody, a TandAb, etc.) capable of binding an epitope of human CD16 (a “CD16 Binding Molecule”). The present invention is further directed to CD 16 Binding Molecules that are capable of binding an epitope of human CD16 and one or more epitope(s) of a Disease Antigen (“DA”) (e.g., a “CD16 x DA Binding Molecule”). The present invention is particularly directed to such CD16 x DA Binding Molecules that are antibodies, or that comprise an Epitope Binding Domain thereof, or are diabodies (including DART® diabodies), bispecific antibodies, TandAbs, other multispecific binding molecules (e.g., trivalent TRIDENT™ molecules), etc. The invention particularly concerns CD16 x DA Binding Molecules that are capable of binding a Disease Antigen that is a Cancer Antigen or a Pathogen-Associated Antigen in addition to being able to bind CD 16. The invention particularly concerns the use of such CD16 and CD16 x DA Binding Molecules in the treatment of cancer and pathogen-associated diseases. The present invention is also directed to pharmaceutical compositions that comprise such molecule(s).
A110 mg QD and platinum-based chemotherapy. A 110 mg in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21day cycles (every 3 weeks) for 4 cycles, followed by A 110mg daily with pemetrexed maintenance (500 mg/m2) every 3 weeks. Dose may be reduced to allow for the management of IP related toxicity.
PROBLEM TO BE SOLVED: To obtain a creamy, non-oily, smooth, non-tacky and anhydrous gel- like composition not containing a wax and stable with time. SOLUTION: This composition contains (a) an organo-modified clay, (b) the spongy hollow thermoplastic particles of a polymer or copolymer formed from one or more ethylenic unsaturated bond-containing monomer or monomers, and (c) pyrogenic silica in a wax-free fatty phase. The fatty phase (e.g. a silicone oil) as a base material for the composition is contained in an amount of 60-80 wt.%. The component (a) comprises the reaction product of hectorite or montmorillonite with a quaternary ammonium salt. The component (b) is e.g. spongy vinylidene chloride-acrylonitrile copolymer having a particle diameter of 1-100 μm and a density of 15-200 kg/cm<3> , and is contained in an amount of 0.1-3 wt.%. The component (c) is contained in an amount of 0.1-3 wt.%.  The composition is suitably further formulated with conventional components and subsequently processed into make-up product bases, skin and/or face care product bases, and/or dermatologic compositions.
In clinical trials of 2 to 52 weeks' duration, epistaxis was observed more frequently in patients treated with DYMISTA than those who received placebo [see Adverse Reactions (6)].

Instances of nasal ulceration and nasal septal perforation have been reported in patients following the nasal application of corticosteroids. There were no instances of nasal ulceration or nasal septal perforation observed in clinical trials with DYMISTA.

Because of the inhibitory effect of corticosteroids on wound healing, patients who have experienced recent nasal ulcers, nasal surgery, or nasal trauma should avoid use of DYMISTA until healing has occurred.

In clinical trials with fluticasone propionate administered nasally, the development of localized infections of the nose and pharynx with Candida albicans has occurred. When such an infection develops, it may require treatment with appropriate local therapy and discontinuation of treatment with DYMISTA. Patients using DYMISTA over several months or longer should be examined periodically for evidence of Candida infection or other signs of adverse effects on the nasal mucosa.
Subjects will be randomized to the treatment or placebo group. The treatment is a capsule taken by mouth once a day for 6 months.
BACKGROUND: Open heart surgery is a potentially traumatic experience for patients, thus posing a real risk to both the patient's physical and mental health as well as bodily integrity. All of these can greatly affect the emotional relationship to the sternotomy scar, the physical aspect of self-representation. Sternotomy scars mark patients for life, yet our knowledge of patients' subjective experiences is unknown.
METHOD: In our case study, we explore the embodied experiences of a woman (42) who underwent open heart surgery with the method of interpretative phenomenological analysis combined with drawings.
RESULTS: The body and the bodily experiences play a prominent role in the formation, healing process, and symbolism of a scar. The central core of the traumatic experience of open heart surgery is the attack against the patient's sensation of bodily integrity. The interviewee experiences the surgery as abuse committed on her body, a memory that is deeply etched both in the physical memory and in the form of a scar on the skin.
CONCLUSION: Based on our study, it seems that the corporeal dimension of posttraumatic growth may develop after the traumatic experience of heart surgery, in which bodily intimacy with oneself and Significant Others plays a major role. In this case study, the objective reality of the heart as "sick" flesh and the "broken, pierced" bone (Körper), as well as the dissociation-and then its integration-of the lived, living body experience (Leib) are outlined. Our case study was analysed in the theoretical framework of phenomenology and psychoanalysis.
FIELD: pharmacology. SUBSTANCE: essence of this process resides in using gases and liquid contained in stock to be processed as extractant, extracting biologically active matter, introducing concentrated extractant at least one time into stock being processed on side opposing outflow of vaporous mixture for repeatedly reacting it with extractant. Apparatus designed for this process includes main reservoir, branch pipe positioned coaxially relative to main reservoir and having radial openings uniformly spaced throughout its length and communicating main reservoir with branch pipe, and partition dividing it into two isolated chambers. First chamber communicates with main cooler via first distributing unit. Second chamber communicates via second distributing unit either with auxiliary reservoir employed for collecting finished product or biologically active matter separator that communicates with main cooler via damping reservoir whose air chamber is in communication with vacuum pump. EFFECT: more sophisticated technique. 10 cl, 1 dwg
The urinary volume and residual urine volume are pieces of information that can provide relevant clinical data for dogs and cats, especially those hospitalized. Thus, the present study aimed to evaluate mathematical formulas described in human and veterinary literature to estimate urinary volume in dogs and experimental models. For this purpose, nine male dog cadavers and twelve experimental models were used to evaluate residual volume, small, medium, and large, using three different formulas. Data were obtained by three different examiners: two ultrasonographers and one nonultrasonographer. Each examiner recorded three longitudinal and transverse images, obtaining measurements of width, length, and height at each proposed volume. The measurements were then averaged, and the result was added to the formulas, thus estimating urinary volume. All three formulas achieved higher accuracy in estimating smaller volumes, with a gradual decrease as urinary volume increased. The error of all formulas was less than 10%, even when compared with evaluations in experimental models and dogs. There was variation in estimation between ultrasonographers and nonultrasonographer examiners; however, this variation was low, allowing for the assertion that both can apply the technique. Thus, it is concluded that estimating urinary bladder volume using mathematical formulas and 2D ultrasound is accurate and, therefore, an alternative and viable option for evaluating the urinary tract.
<P>PROBLEM TO BE SOLVED: To provide a radio IC tag with a long communication distance by mounting a small-sized radio IC inlet on a package whose seal material is a thin film of metal such as aluminum without the need for addition of a component.  <P>SOLUTION: In a tablet PTP package 1, many tablets 2 are packaged by a resin sheet PVC 3 and an aluminum sheet 4. A thin and long space pattern 5 is formed to part of the aluminum sheet 4 on a lower side of the package to provide an island region 6 acting like an antenna. The small-sized radio IC inlet 9 formed by mounting an IC chip 8 to a small-sized antenna 7 is arranged to the rear side (package upper side) of the aluminum sheet 4 at a part where the island region 6 is formed. Since the antenna formed with the island region 6 and the small-sized radio IC inlet 9 are electrostatically coupled by using the resin sheet PVC 3 for a dielectric body, a radio IC tag 10 is configured. Thus, holding up a reader/writer (not shown) onto the radio IC tag 10 allows a user to read information of the tablet PTP package 1.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The farnesoid X receptor (FXR), a ligand-activated transcription factor, plays a crucial role in regulating bile acid metabolism within the enterohepatic circulation. Beyond its involvement in metabolic disorders and immune imbalances affecting various tissues, FXR is implicated in microbiota modulation, gut-to-brain communication, and liver disease. The liver, as a pivotal metabolic and detoxification organ, is susceptible to damage from factors such as alcohol, viruses, drugs, and high-fat diets. Chronic or recurrent liver injury can culminate in liver fibrosis, which, if left untreated, may progress to cirrhosis and even liver cancer, posing significant health risks. However, therapeutic options for liver fibrosis remain limited in terms of FDA-approved drugs. Recent insights into the structure of FXR, coupled with animal and clinical investigations, have shed light on its potential pharmacological role in hepatic fibrosis. Progress has been achieved in both fundamental research and clinical applications. This review critically examines recent advancements in FXR research, highlighting challenges and potential mechanisms underlying its role in liver fibrosis treatment.
The object is to provide: a safe immunostimulating agent which can be used as a pharmaceutical or a food material; a method for production of the immunostimulating agent; and a novel application of a coffee extract residue. Disclosed is an immunostimulating agent comprising a coffee extract as an active ingredient. Preferably, the coffee extract is an extract containing arabinogalactan. The immunostimulating effect of the immunostimulating agent relies on the promotion of the proliferation of an immunocompetent cell such as a macrophage. The immunocompetent cell is preferably any one selected from a macrophage-like strain RAW264 or J774.1, a murine splenic cell, a murine peritoneal macrophage and a murine dendritic cell. A composition containing the immunostimulating agent can be used as a composition such as a pharmaceutical composition, a food composition and a cosmetic composition.
The patients who will be randomized to CCBT-I group will get Cleveland Clinic CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program). The program involves a 6-week effective sleep therapy, an online sleep log and daily sleep score, six specially crafted relaxation practices, daily sleep improvement recommendations, activities to help the patient get the sleep needed, daily e-mails from the patient's program coach, daily articles to help the patient get the most out of the program and a mobile application for easy sleep tracking.